GIBSON DUNN

Gibson Dunn Advises 89bio on Its Up to $3.5 Billion Sale to Roche Holdings

Firm News | September 19, 2025

Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc. Our corporate team is led by partners Branden Berns, Ryan Murr, and Evan D'Amico and includes partners Karen Spindler, Melanie Neary, and George Sampas and associates Jonathan Sapp, Ayushi Sutaria, Lauren Navarro, and Risa Nakagawa. Partner Sean Feller and of counsel Alli Balick are advising on employee compensation and benefits matters; partner Pamela Lawrence Endreny and associate Bree Gong are advising on tax matters; and Michael J. Perry is advising on U.S. and foreign antitrust and competition matters.

Related People

Branden C. Berns

Ryan A. Murr

Evan M. D'Amico

Karen A. Spindler

Melanie E. Neary

George Sampas

Ayushi Sutaria

Lauren Navarro

Risa Nakagawa

Sean C. Feller

Alli Balick

Pamela Lawrence Endreny

Michael J. Perry

Related Capabilities

Mergers and Acquisitions

Life Sciences

Executive Compensation and Employee Benefits

Tax

Antitrust and Competition

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**